{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T23:48:07Z","timestamp":1787615287823,"version":"build-2736575974"},"reference-count":82,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2020,12,27]],"date-time":"2020-12-27T00:00:00Z","timestamp":1609027200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pediatric Allergy Immunology"],"published-print":{"date-parts":[[2021,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Atopic dermatitis (AD) is a common skin disease during infancy, which imposes a considerable burden on patients, their families, and the society, requiring effective treatment options that result in rapid and sustained symptom relief. Additionally, early treatment may prevent the development of atopic comorbidities by restoring the skin barrier. Currently, topical standard\u2010of\u2010care for AD in infants includes emollients and topical corticosteroids (TCS) to treat and reduce the risk of flares. However, only few have been approved for infants and long\u2010term maintenance therapy with TCS is not indicated due to potential local and systemic side effects, including skin atrophy. Accordingly, the recently updated European guidelines for treatment of AD recommend topical calcineurin inhibitors (TCIs) for long\u2010term use, treatment of sensitive skin areas, and for use in the pediatric population. Evidence on the use of TCIs for infants has almost been exclusively collected for pimecrolimus, with &gt;4000 infants evaluated in clinical trials, consistently confirming that pimecrolimus is a safe and effective treatment for infants with AD. Nevertheless, its use is still restricted in most countries to children above the age of 2\u00a0years due to initial and mostly theoretical safety concerns. Based on a careful review of the available evidence of clinical trials, post\u2010marketing surveillance, and epidemiological studies, an Expert Panel of European dermatologists and pediatric allergologists concluded that these safety concerns are no longer valid. Therefore, pimecrolimus offers a safe and effective alternative to TCS in infants aged 3\u00a0months and above, and labeling restrictions in this age group are no longer justified.<\/jats:p>","DOI":"10.1111\/pai.13422","type":"journal-article","created":{"date-parts":[[2020,11,29]],"date-time":"2020-11-29T22:14:38Z","timestamp":1606688078000},"page":"414-424","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Unmet medical needs in the treatment of atopic dermatitis in infants: An Expert consensus on safety and efficacy of pimecrolimus"],"prefix":"10.1111","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1397-1626","authenticated-orcid":false,"given":"Thomas","family":"Luger","sequence":"first","affiliation":[{"name":"Department of Dermatology University of M\u00fcnster M\u00fcnster Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Augustin","sequence":"additional","affiliation":[{"name":"University Medical Centre Hamburg\u2010Eppendorf Hamburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Lambert","sequence":"additional","affiliation":[{"name":"Department of Dermatology University Hospital of Antwerp University of Antwerp Antwerp Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carle","family":"Paul","sequence":"additional","affiliation":[{"name":"Department of Dermatology Toulouse University Toulouse France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Pincelli","sequence":"additional","affiliation":[{"name":"Laboratory of Cutaneous Biology Department of Surgical, Medical, Dental and Morphological Sciences University of Modena and Reggio Emilia Modena Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Torrelo","sequence":"additional","affiliation":[{"name":"Department of Dermatology Hospital Infantil Universitario Ni\u00f1o Jes\u00fas Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Vestergaard","sequence":"additional","affiliation":[{"name":"Department of Dermatology Aarhus University Hospital Aarhus Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Wahn","sequence":"additional","affiliation":[{"name":"Department for Pediatric Pneumology and Immunology Charit\u00e9 Medical University Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Werfel","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergy Hannover Medical School Hannover Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,12,27]]},"reference":[{"key":"e_1_2_13_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00149-X"},{"key":"e_1_2_13_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2016.07.012"},{"key":"e_1_2_13_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.iac.2010.05.004"},{"key":"e_1_2_13_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2006.02.031"},{"key":"e_1_2_13_6_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13223-018-0281-6"},{"key":"e_1_2_13_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-64804-0_3"},{"key":"e_1_2_13_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.iac.2014.09.008"},{"key":"e_1_2_13_9_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21082867"},{"key":"e_1_2_13_10_1","doi-asserted-by":"publisher","DOI":"10.1080\/21556660.2019.1619570"},{"key":"e_1_2_13_11_1","doi-asserted-by":"publisher","DOI":"10.5114\/pdia.2013.38355"},{"key":"e_1_2_13_12_1","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/354250"},{"key":"e_1_2_13_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.06.013"},{"key":"e_1_2_13_14_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2018.4145"},{"key":"e_1_2_13_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.05.028"},{"key":"e_1_2_13_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14888"},{"key":"e_1_2_13_17_1","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1L067"},{"key":"e_1_2_13_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.13189"},{"key":"e_1_2_13_19_1","unstructured":"ELIDEL\u00ae(pimecrolimus) Cream 1% for topical use; Highlights of prescribing information 2014. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/021302s018lbl.pdf. Accessed 23 June 2020."},{"key":"e_1_2_13_20_1","unstructured":"European Medicines Agency. ELIDEL\u00ae: Summary of product characteristics. 2006. https:\/\/www.ema.europa.eu\/en\/documents\/referral\/elidel\u2010article\u201031\u2010referral\u2010annex\u2010i\u2010ii\u2010iii_en.pdf."},{"key":"e_1_2_13_21_1","unstructured":"PROTOPIC\u00ae(tacrolimus) ointment 0.03% ointment 0.1%; Prescribing information 2011. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/050777s018lbl.pdf. Accessed 23 June 2020."},{"key":"e_1_2_13_22_1","unstructured":"PROTOPIC\u00ae(tacrolimus) ointment 0.03%; Summary of Product Characteristics 2006. https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/protopic\u2010epar\u2010product\u2010information_en.pdf. Accessed 23 June 2020."},{"key":"e_1_2_13_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.0906-6705.2004.00269.x"},{"key":"e_1_2_13_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2009.07.015"},{"key":"e_1_2_13_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/pai.12331"},{"key":"e_1_2_13_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2019.01.003"},{"key":"e_1_2_13_27_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2222.1998.00371.x"},{"key":"e_1_2_13_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/pai.12410"},{"key":"e_1_2_13_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2013.298"},{"key":"e_1_2_13_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2014.10.007"},{"key":"e_1_2_13_31_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12887-016-0673-z"},{"key":"e_1_2_13_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/pde.12867"},{"key":"e_1_2_13_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2014.08.011"},{"key":"e_1_2_13_34_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2013.148"},{"key":"e_1_2_13_35_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2015-1444"},{"key":"e_1_2_13_36_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapediatrics.2017.0556"},{"key":"e_1_2_13_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32984-8"},{"key":"e_1_2_13_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2015.03.040"},{"key":"e_1_2_13_39_1","first-page":"113","volume-title":"Allergy, Immunity and Tolerance in Early Childhood: The First Steps of the Atopic March","author":"Barnes KC","year":"2015"},{"key":"e_1_2_13_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2016.08.022"},{"issue":"448","key":"e_1_2_13_41_1","first-page":"e430","article-title":"Association of atopic dermatitis with depression, anxiety, and suicidal ideation in children and adults: a systematic review and meta\u2010analysis","volume":"79","author":"Ronnstad ATM","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"e_1_2_13_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.08.063"},{"key":"e_1_2_13_43_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3511"},{"key":"e_1_2_13_44_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2004-0374"},{"key":"e_1_2_13_45_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3102"},{"key":"e_1_2_13_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2018.12.017"},{"key":"e_1_2_13_47_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3257"},{"key":"e_1_2_13_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2004.08.015"},{"key":"e_1_2_13_49_1","doi-asserted-by":"publisher","DOI":"10.1067\/mai.2002.126500"},{"key":"e_1_2_13_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2004.09.016"},{"key":"e_1_2_13_51_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4632.2004.02121.x"},{"key":"e_1_2_13_52_1","doi-asserted-by":"publisher","DOI":"10.1067\/mpd.2003.65"},{"key":"e_1_2_13_53_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-3038.2005.00306.x"},{"key":"e_1_2_13_54_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2006.01383.x"},{"key":"e_1_2_13_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0301-0546(05)73248-1"},{"key":"e_1_2_13_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2004.01.051"},{"key":"e_1_2_13_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2004.12.038"},{"key":"e_1_2_13_58_1","doi-asserted-by":"publisher","DOI":"10.1159\/000381948"},{"key":"e_1_2_13_59_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4632.2011.05015.x"},{"key":"e_1_2_13_60_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2014-1990"},{"key":"e_1_2_13_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2007.09.004"},{"key":"e_1_2_13_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2003.07.013"},{"key":"e_1_2_13_63_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2001.04133.x"},{"key":"e_1_2_13_64_1","doi-asserted-by":"publisher","DOI":"10.1136\/adc.88.11.969"},{"key":"e_1_2_13_65_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0625.2006.00398.x"},{"key":"e_1_2_13_66_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1346-8138.2007.00259.x"},{"key":"e_1_2_13_67_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-1470.2005.00128.x"},{"key":"e_1_2_13_68_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2005-1188"},{"key":"e_1_2_13_69_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2004.08.046"},{"key":"e_1_2_13_70_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-013-0020-1"},{"key":"e_1_2_13_71_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jid.5700622"},{"key":"e_1_2_13_72_1","doi-asserted-by":"publisher","DOI":"10.1159\/000209289"},{"key":"e_1_2_13_73_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2009.02.028"},{"key":"e_1_2_13_74_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2014.4305"},{"issue":"2","key":"e_1_2_13_75_1","first-page":"AB3","article-title":"Lymphoma among patients with atopic dermatitis treated with topical corticosteroids and\/or topical calcineurin inhibitors [abstract]","volume":"64","author":"Arana A","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"e_1_2_13_76_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40272-013-0013-9"},{"key":"e_1_2_13_77_1","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1M278"},{"key":"e_1_2_13_78_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2010.09887.x"},{"key":"e_1_2_13_79_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.02.1116"},{"key":"e_1_2_13_80_1","doi-asserted-by":"publisher","DOI":"10.1159\/000100879"},{"key":"e_1_2_13_81_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.03.075"},{"key":"e_1_2_13_82_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12887-016-0607-9"},{"key":"e_1_2_13_83_1","unstructured":"Product monograph including patient medication information Elidel\u00ae(Pimecrolimus) Cream 1% 2019. https:\/\/pdf.hres.ca\/dpd_pm\/00053301.PDF. Accessed 23 June 2020."}],"container-title":["Pediatric Allergy and Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/pai.13422","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/pai.13422","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/pai.13422","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T19:51:07Z","timestamp":1693338667000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/pai.13422"}},"subtitle":[],"editor":[{"given":"Motohiro","family":"Ebisawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2020,12,27]]},"references-count":82,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["10.1111\/pai.13422"],"URL":"https:\/\/doi.org\/10.1111\/pai.13422","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.1111\/PAI.13422\/v2\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/PAI.13422\/v1\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/PAI.13422\/v1\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/PAI.13422\/v1\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/PAI.13422\/v2\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/PAI.13422\/v2\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/PAI.13422\/v2\/decision1","asserted-by":"object"}]},"ISSN":["0905-6157","1399-3038"],"issn-type":[{"value":"0905-6157","type":"print"},{"value":"1399-3038","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,27]]},"assertion":[{"value":"2020-09-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-11-18","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-12-27","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}